|
MechanismGP1BA inhibitors |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 重组安菲博肽注射液Ⅰ期单次给药人体耐受性与药代动力学临床研究
[Translation] Phase I single-dose human tolerability and pharmacokinetics clinical study of recombinant Anfibopeptide injection
主要目的:评价重组安菲博肽注射液在中国健康成年参与者单次用药的安全性及耐受性;次要目的:1.评价重组安菲博肽在中国健康成年参与者单次用药的人体药代动力学(PK)特征;2.评价重组安菲博肽在中国健康成年参与者单次用药的药效动力学(PD)特征:血小板聚集抑制率、GP-Ib受体结合率;3.重组安菲博肽注射液免疫原性(抗药抗体[ADA]、中和抗体[Nab])。
[Translation] Primary objective: To evaluate the safety and tolerability of a single dose of recombinant amprolium-1 injection in healthy adult participants in China; Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of a single dose of recombinant amprolium-1 injection in healthy adult participants in China; 2. To evaluate the pharmacodynamic (PD) characteristics of a single dose of recombinant amprolium-1 injection in healthy adult participants in China: platelet aggregation inhibition rate and GP-Ib receptor binding rate; 3. To evaluate the immunogenicity of recombinant amprolium-1 injection (antidrug-resistant antibody [ADA], neutralizing antibody [Nab]).
100 Clinical Results associated with Foshan Pujin Biotechnology Co., Ltd.
0 Patents (Medical) associated with Foshan Pujin Biotechnology Co., Ltd.
100 Deals associated with Foshan Pujin Biotechnology Co., Ltd.
100 Translational Medicine associated with Foshan Pujin Biotechnology Co., Ltd.